×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AQST – aquestive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AQST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/21
04:47 pm
aqst
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
Low
Report
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
4/21
03:59 pm
aqst
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
4/21
03:41 pm
aqst
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
Low
Report
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
4/21
09:00 am
aqst
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
Low
Report
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
4/20
04:00 pm
aqst
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
Low
Report
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
4/20
12:00 pm
aqst
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
4/20
09:00 am
aqst
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
Low
Report
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
4/20
08:00 am
aqst
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE) Announced by Holzer & Holzer, LLC
Low
Report
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE) Announced by Holzer & Holzer, LLC
Date
Time
Symbol
Company Name
Action
%Chg
3/4/2026
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
-2.1%
aquestive therapeutics, inc.
11/5/2025
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
2.2%
aquestive therapeutics, inc.
8/11/2025
04:01 pm
AQST
aquestive therapeutics, inc.
BEAT
Report
2.8%
aquestive therapeutics, inc.
5/12/2025
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
-19.6%
aquestive therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
03:54 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Boyd Peter E.
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Boyd Peter E.
4/13
03:54 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Barber Daniel
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Barber Daniel
4/13
03:53 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: TOTH A ERNEST JR
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: TOTH A ERNEST JR
4/13
03:53 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Jung Cassie
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Jung Cassie
4/13
03:52 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Korczynski Sherry
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: Korczynski Sherry
4/13
03:52 pm
aqst
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: BRAENDER LORI J
Low
Report
Form 4 Aquestive Therapeutics, For: Mar 07 Filed by: BRAENDER LORI J
4/10
09:56 am
aqst
Form 3 Aquestive Therapeutics, For: Apr 02 Filed by: Zalewski Thomas A.
Low
Report
Form 3 Aquestive Therapeutics, For: Apr 02 Filed by: Zalewski Thomas A.
3/30
07:45 am
aqst
Form 8-K Aquestive Therapeutics, For: Mar 30
Low
Report
Form 8-K Aquestive Therapeutics, For: Mar 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Form 8-K Aquestive Therapeutics, For: Nov 05
23.6%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
TOP News Decliners
3/11
Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.450 ActVsEst (0.030) - Miss
-40.0%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: